📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. (2017)

First Author: Cunningham D

Attributed to: The MRC ConDuCT-II Hub. COllaboration and iNnovation in DiffiUlt and Complex randomised controlled Trials In Invasive procedures funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(17)30043-8

PubMed Identifier: 28163000

Publication URI: http://europepmc.org/abstract/MED/28163000

Type: Journal Article/Review

Volume: 18

Parent Publication: The Lancet. Oncology

Issue: 3

ISSN: 1470-2045